BR112020005964A2 - intermediário de linagliptina cristalina e processo para preparação de linagliptina - Google Patents

intermediário de linagliptina cristalina e processo para preparação de linagliptina Download PDF

Info

Publication number
BR112020005964A2
BR112020005964A2 BR112020005964-1A BR112020005964A BR112020005964A2 BR 112020005964 A2 BR112020005964 A2 BR 112020005964A2 BR 112020005964 A BR112020005964 A BR 112020005964A BR 112020005964 A2 BR112020005964 A2 BR 112020005964A2
Authority
BR
Brazil
Prior art keywords
formula
linagliptin
crystalline form
reaction mass
linagliptin intermediate
Prior art date
Application number
BR112020005964-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Venkata Raghavendracharyulu Palle
Shanmughasamy Rajmahendra
Dharshan Jakkali Chandregowda
Thangarasu Ponnusamy
Original Assignee
Biocon Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Limited filed Critical Biocon Limited
Publication of BR112020005964A2 publication Critical patent/BR112020005964A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112020005964-1A 2017-09-27 2018-09-27 intermediário de linagliptina cristalina e processo para preparação de linagliptina BR112020005964A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201741034292 2017-09-27
IN201741034292 2017-09-27
PCT/IB2018/057484 WO2019064214A1 (en) 2017-09-27 2018-09-27 INTERMEDIATE OF CRYSTALLINE LINAGLIPTIN AND PROCESS FOR THE PREPARATION OF LINAGLIPTIN

Publications (1)

Publication Number Publication Date
BR112020005964A2 true BR112020005964A2 (pt) 2020-10-06

Family

ID=65903063

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020005964-1A BR112020005964A2 (pt) 2017-09-27 2018-09-27 intermediário de linagliptina cristalina e processo para preparação de linagliptina

Country Status (10)

Country Link
US (1) US11040974B2 (cg-RX-API-DMAC7.html)
JP (1) JP2020535193A (cg-RX-API-DMAC7.html)
KR (1) KR20200092946A (cg-RX-API-DMAC7.html)
CN (1) CN111511743A (cg-RX-API-DMAC7.html)
AU (1) AU2018343236A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020005964A2 (cg-RX-API-DMAC7.html)
CA (1) CA3076980A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020004050A (cg-RX-API-DMAC7.html)
RU (1) RU2020114890A (cg-RX-API-DMAC7.html)
WO (1) WO2019064214A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110684026A (zh) * 2019-10-24 2020-01-14 扬子江药业集团上海海尼药业有限公司 一种利格列汀的工业化制备方法
CN110872292B (zh) * 2019-11-30 2022-01-25 江苏君若药业有限公司 一条合成糖尿病药物利拉利汀的路线
EP4349837A1 (en) 2022-10-05 2024-04-10 Zaklady Farmaceutyczne "Polpharma" S.A. A pharmaceutical intermediate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
IN2013MU02055A (cg-RX-API-DMAC7.html) * 2013-06-18 2015-07-03 Cadila Healthcare Ltd
WO2015011609A1 (en) * 2013-07-23 2015-01-29 Ranbaxy Laboratories Limited Process for the preparation of linagliptin and an intermediate thereof

Also Published As

Publication number Publication date
JP2020535193A (ja) 2020-12-03
WO2019064214A1 (en) 2019-04-04
KR20200092946A (ko) 2020-08-04
US11040974B2 (en) 2021-06-22
US20200354363A1 (en) 2020-11-12
RU2020114890A (ru) 2021-10-27
CA3076980A1 (en) 2019-04-04
CN111511743A (zh) 2020-08-07
MX2020004050A (es) 2020-11-06
AU2018343236A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
JP7036846B2 (ja) Cdk阻害剤の結晶質形態
EP4570805A1 (en) Tricyclic compounds and medical use thereof
EP2985277B1 (en) Method for preparing an atropisomer of a pyrrole derivative
CN119462648A (zh) 四氢吡啶并嘧啶类化合物及其制备方法和应用
CA3130247A1 (en) Fgfr inhibitor compound in solid form and preparation method therefor
AU2016258388B2 (en) Novel crystal of uracil compound
JP2023511105A (ja) 2-[3-[4-アミノ-3-(2-フルオロ-4-フェノキシ-フェニル)-1h-ピラゾロ[3,4-d]ピリミジン-1-イル]ピペリジン-1-カルボニル]-4-メチル-4-[4-(オキセタン-3-イル)ピペラジン-1-イル]ペンタ-2-エンニトリルの結晶形態
JP6193762B2 (ja) 1−{(2S)−2−アミノ−4−[2,4−ビス(トリフルオロメチル)−5,8−ジヒドロピリド[3,4−d]ピリミジン−7(6H)−イ
EP3315499A1 (en) CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND
JP2018520205A (ja) レンバチニブメシル酸塩の新規結晶形及びその製造方法
WO2017092413A1 (zh) 一种二氨基嘧啶化合物及包含该化合物的组合物
BR112015017963A2 (pt) composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto
EP3322709B1 (en) Crystalline forms of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile salts and preparation thereof
US11040974B2 (en) Crystalline linagliptin intermediate and process for preparation of linagliptin
JP7618575B2 (ja) N-(5-((4-エチルピペラジン-1-イル)メチル)ピリジン-2-イル)-5-フルオロ-4-(3-イソプロピル-2-メチル-2h-インダゾール-5-イル)ピリミジン-2-アミンおよびその塩の結晶形態および非晶質形態、ならびにその製造方法および治療的使用
EP3604284B1 (en) Crystalline eltrombopag monoethanolamine salt form d
CN112830919B (zh) 苯并哌啶衍生物可药用盐及其制备方法
BR112020006051A2 (pt) formas cristalinas de lenalidomida
EP4644374A1 (en) Naphthylamide compound, and preparation method therefor and use thereof
HK40054619B (en) Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto
HK1241358A1 (en) Crystal of (s)-1-(2-hydroxyethyl)-4-methyl-n- [4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]- 1h-pyrrole-3-carboxamide
HK1221214B (en) Method for preparing an atropisomer of a pyrrole derivative
HK1187046B (en) Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
HK1187046A (en) Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate
BR122020009305B1 (pt) Forma cristalina de 6-(6-aminopirazin-2-il)-n-(4-(4-(oxetan-3-il)piperazin-1- il)fenil)imidazo[1,2-a]pirazin-8-amina, composição farmacêutica, e, uso de uma forma cristalina

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements